MBL Health applies a patient-first, tech-enabled approach to modernize and humanize clinical research
Masood Sahibzada, Founder
Technology, evolving regulations, and an increasing emphasis on patient experience are reshaping the clinical trial services industry. With the rise of Decentralized Clinical Trials (DCTs) and the growing use of digital tools for data collection and analysis, the clinical research landscape is undergoing significant transformation. At the forefront of this shift is MBL Health, a healthtech company applying a patient-first, tech-enabled approach to modernize and humanize clinical research.
Bridging the Gap Between Pharma & Patients
MBL Health, headquartered in the UAE with operations in India, is focused on narrowing the gap between pharmaceutical companies and the patients they serve, particularly in the rare and hard-to-treat disease space. The company recognizes that clinical trial recruitment remains one of the most challenging aspects of research, especially in rare disease areas where patient communities are often dispersed, underrepresented, or unaware of opportunities to participate in clinical studies.
With the philosophy that “Health is Human”, MBL Health approaches patient engagement through a blend of empathy, personalization, and technology. By leveraging a data-driven strategy, the company enables sponsors to connect more effectively with qualified participants, often reaching individuals who fall outside traditional investigator networks and would otherwise be overlooked.
MBL Health supports high-quality patient recruitment and referrals through its tech-enabled solutions, offering educational resources and facilitating real-world participation in clinical research. Its approach is rooted in personalized patient journeys and curated content that empower individuals and their families to engage meaningfully and confidently with the research process.
A Robust Technology Ecosystem: JAVIS and DupCheck+
Central to MBL Health’s value proposition is its proprietary technology infrastructure. The JAVIS platform offers a 360-degree view of each participant and streamlines clinical trial operations from initial engagement to retention. It supports subject tracking, data visibility, and real-time updates, enabling sponsors, sites, and investigators to coordinate with greater efficiency.
Complementing this is DupCheck+, MBL Health’s fraud-prevention system designed to identify duplicate or professional patients. The tool uses advanced browser and device fingerprinting, IP behavior monitoring, and machine learning to detect suspicious patterns in real time. This functionality has proven especially useful in decentralized studies, where participant authenticity is critical to trial integrity.
MBL Health applies a patient-first, tech-enabled approach to modernize and humanize clinical researchMasood Sahibzada, Founder
Together, these platforms underpin MBL Health’s digital-first, patient-centered strategy and differentiate the company in an increasingly competitive field.
Strategic Vision Rooted in Empathy & Inclusion
MBL Health combines cutting-edge technology with human-centered design to increase access and participation in rare disease trials. By meeting patients where they are, geographically, digitally, and emotionally, the company builds trust and drives meaningful engagement.
Its model blends localized outreach with digital infrastructure, enabling sponsors to reach more diverse populations while optimizing trial performance. From patient education to enrollment and long-term follow-up, MBL Health delivers scalable solutions that are both inclusive and effective.
Flexible, Inclusive, & Global
MBL Health’s services are adaptable across various therapeutic areas, including metabolic disorders, oncology, and neurology. The company collaborates with clinical teams to ensure that trial designs are culturally sensitive, protocol-compliant, and aligned with patient needs.
What makes MBL Health particularly unique is its ability to reach self-referring patients, those outside traditional site networks. This capability not only accelerates recruitment but also enriches study populations with real-world diversity. The company has supported clinical and post-approval research in conditions such as Myasthenia Gravis, CAH, and Canavan Disease, among others.
Security, Integrity, & Trust
Security and transparency are at the core of MBL Health’s digital framework. The company provides tools such as eConsent and mobile data capture that simplify participation while protecting sensitive health information. Sponsors benefit from secure, intuitive systems that enable faster study execution, cost reduction, and cleaner data, all while building trust with participants.
DupCheck+ plays a vital role in preserving data integrity by preventing enrollment fraud, which is a growing issue in remote-first studies. Its integration-ready design allows for real-time screening, fraud flagging, and cross-study de-duplication.
Looking Ahead
As MBL Health looks to the future, the company is expanding into Asia and the Middle East and investing in AI-powered patient matching to further improve recruitment speed and precision. These systems will support real-time referral scoring, digital pre-screening, and smarter triage for complex studies.
In parallel, the company is building strategic partnerships across the rare disease ecosystem, aligned with its broader mission to make decentralized, inclusive, and technology-driven clinical trials accessible anywhere in the world.
“We’re working to make clinical trials easier to join, more effective, and built around what patients need, so we can improve care and advance research worldwide”, concludes Masood Sahibzada, Founder, MBL Health.
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")
